EDITOR'S RECOMMENDATION

Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease

调整二肽基肽酶IV抑制剂的剂量在2型糖尿病合并慢性肾病患者中的经济效益

Sun Joon Moon

orcid.org/0000-0002-6286-7254

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Search for more papers by this author

Young Min Cho,

Corresponding Author

Young Min Cho

[email protected]

orcid.org/0000-0002-2331-6126

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Correspondence

Young Min Cho, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.

Email: [email protected]

Search for more papers by this author

Sun Joon Moon,

Sun Joon Moon

orcid.org/0000-0002-6286-7254

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Search for more papers by this author

Young Min Cho,

Corresponding Author

Young Min Cho

[email protected]

orcid.org/0000-0002-2331-6126

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Correspondence

Young Min Cho, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.

Email: [email protected]

Search for more papers by this author

First published: 20 May 2020

https://doi.org/10.1111/1753-0407.13067

Share a link

Email
Wechat
Bluesky

摘要

主要内容

二肽基肽酶IV抑制剂(DPP-IVi)可用于2型糖尿病合并慢性肾脏病(T2D CKD)患者的治疗, 可以根据药物药代动力学特性调整或不调整剂量。鉴于DPP-IVi是一大类药物, 在T2D CKD患者中恰当使用需根据肾功能调整用量的DPP-IVi(RDA DPP-IVi), 而不是使用NRDA DPP-IVi, 将可以节约相当大的成本。

虽然一些研究揭示了T2D CKD患者DPP-IVi的处方模式, 但这些研究没有从经济影响的角度进行分析, 也没有使用具有全国代表性的数据。作者利用国家数据进行了一项真实的观察性研究, 以评估T2D CKD患者的DPP-IVi的处方模式, 以分析RDA DPP-IVi代替NRDA DPP-IVi的处方的经济影响。

Supporting Information

REFERENCES

1Spanopoulos D, Barrett B, Busse M, Roman T, Poole C. Prescription of DPP-4 inhibitors to type 2 diabetes mellitus patients with renal impairment: a UKprimary care experience. Clin Ther. 2018; 40(1): 152-154.
10.1016/j.clinthera.2017.11.009
CAS PubMed Web of Science® Google Scholar
2Tebboth A, Lee S, Scowcroft A, et al. Demographic and clinical characteristics of patients with type 2 diabetes mellitus initiating dipeptidyl peptidase 4 inhibitors: a retrospective study of UKgeneral practice. Clin Ther. Aug 2016; 38(8): 1825-1832.e1815.
10.1016/j.clinthera.2016.07.006
PubMed Web of Science® Google Scholar
3Huang H, Shetty S, Bauer E, Lang K. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Curr Med Res Opin. Jun 2018; 34(6): 1021-1027.
10.1080/03007995.2017.1416346
CAS PubMed Web of Science® Google Scholar
4Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014; 36:e2014008.
10.4178/epih/e2014008
PubMed Google Scholar
5Kweon S, Kim Y, Jang MJ, et al. Data resource profile: the Korea National Health and nutrition examination survey (KNHANES). Int J Epidemiol. Feb 2014; 43(1): 69-77.
10.1093/ije/dyt228
PubMed Web of Science® Google Scholar
6Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018, 43:dci180007.
Google Scholar
7Ko SH, Kim DJ, Park JH, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study. Medicine. 2016; 95(27):e4018.
10.1097/MD.0000000000004018
CAS PubMed Web of Science® Google Scholar
8Ou HT, Chang KC, Liu YM, Wu JS. Recent trends in the use of antidiabetic medications from 2008 to 2013: a nation-wide population-based study from Taiwan. J Diabetes. Mar 2017; 9(3): 256-266.
10.1111/1753-0407.12408
PubMed Web of Science® Google Scholar
9Patorno E, Gopalakrishnan C, Bartels DB, Brodovicz KG, Liu J, Schneeweiss S. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. Endocrinol Diabetes Metab. 2018; 1(1):e00005.
10.1002/edm2.5
PubMed Google Scholar
10Walker SR, Komenda P, Khojah S, et al. Dipeptidyl Peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials. Nephron. 2017; 136(2): 85-94.
10.1159/000454683
CAS PubMed Web of Science® Google Scholar

Volume12, Issue9

September 2020

Pages 645-648

This article also appears in:

Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease

调整二肽基肽酶IV抑制剂的剂量在2型糖尿病合并慢性肾病患者中的经济效益

摘要

主要内容

Supporting Information

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease

调整二肽基肽酶IV抑制剂的剂量在2型糖尿病合并慢性肾病患者中的经济效益

摘要

主要内容

Supporting Information

REFERENCES

References

Related

Information